Home Blog Page 302

Bybit Launches Trade & Hold $TRUMP Campaign Featuring $100,000 Prize Pool and VIP Football Finals Experience

By
Advertorial Desk
-

DUBAI, UAE, June 15, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, has announced the launch of its Trade & Hold $TRUMP campaign, offering eligible participants the opportunity to share up to 100,000 USDT in rewards and compete for a luxury VIP experience at the 2026 Football Finals.

Running from June 11, 2026, at 10:00 a.m. UTC through June 30, 2026, at 11:59 p.m. UTC, the campaign rewards users who trade eligible Spot and Perpetual Futures pairs while maintaining qualifying $TRUMP token holdings in their Unified Trading Account (UTA).

Participants will be ranked based on total eligible trading volume accumulated during the campaign period. The top 50 users who meet the corresponding $TRUMP holding requirements for their final ranking position will share a prize pool of up to 100,000 USDT. In addition to USDT rewards, select top-ranked participants will receive exclusive physical prizes.

The campaign’s grand prize will be awarded to the top-ranked participant and includes a three-day luxury VIP package for the 2026 Football Finals, valued at approximately $100,000. The package features access to a private suite for the July 19 championship match in New Jersey, a three-night stay at the St. Regis New York, luxury chauffeured transportation throughout the weekend, premium dining experiences, a private gala dinner, elite after-party access and additional exclusive experiences.

Participants finishing between second and 16th place will receive a limited-edition $TRUMP Coin Club merchandise set, including a $TRUMP Coin Club sneaker and watch.

The VIP experience will be issued by $TRUMP Coin Club. Featuring $TRUMP Coin Club for this Football Finals campaign, Bybit is providing users with access to compete for exclusive VIP experiences and rewards. The football finals viewing experience is organized independently and is not sponsored by, affiliated with, endorsed by or otherwise associated with FIFA, any national football association, any tournament organizing committee or any governing body associated with the FIFA World Cup™ tournament.

USDT rewards will be distributed to winners’ Bybit Funding Accounts within 20 working days after the campaign concludes. Merchandise prizes will be shipped within 30 days after recipients provide and verify the required shipping information.

As with all digital asset activities, token prices remain subject to market fluctuations. The campaign does not constitute investment advice, a recommendation or an endorsement of any digital asset. Participants are required to comply with Bybit’s Terms of Service throughout the campaign period. More detailed information is available on the website.

The campaign further underscores Bybit’s collaboration with $TRUMP Coin Club, bringing exclusive community experiences and rewards to eligible users.

Disclaimer: The campaign is open exclusively to eligible Bybit users with a Unified Trading Account. Institutional users, market makers, Pro users and affiliates are not eligible to participate. Participants from restricted jurisdictions, including the European Economic Area, are excluded from the promotion.

#Bybit  / #NewFinancialPlatform 

Bybit Launches Trade & Hold $TRUMP Campaign Featuring $100,000 Prize Pool and VIP Football Finals Experience
Bybit Launches Trade & Hold $TRUMP Campaign Featuring $100,000 Prize Pool and VIP Football Finals Experience

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press

For media inquiries, please contact: media@bybit.com

For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

Ucore Rare Metals and Sumitomo Corporation of Americas Announce Strategic Collaboration in Rare Earth Supply Chain

By
Advertorial Desk
-
Halifax, Nova Scotia – Newsfile Corp. – June 15, 2026 – Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) (“Ucore” or the “Company“) is pleased to announce a strategic cooperation framework with Sumitomo Corporation of Americas (“SCOA“) to support the development of a diversified rare earth supply chain across North America and allied markets.

Under the Agreement, signed on June 10, 2026, the companies will collaborate on sourcing rare earth feedstock for Ucore’s Louisiana Strategic Metals Complex (SMC) and downstream offtake development for separated rare earth products. The focus is on selected middle and heavy rare earth elements critical to high-performance magnets and advanced materials applications primarily in Japan while preserving feedstock for additional processing for North American and allied markets.

The collaboration is intended to combine Ucore’s developing RapidSX™ technology platform at its Louisiana (“SMC“) rare earth refinery with SCOA’s global sourcing, logistics, and market access capabilities, including in Japan, as the parties work to support more diversified rare earth supply chains. Furthermore, the companies intend to formally cooperate as project partners in Ucore’s previously announced Global Partnership Initiative with the Government of Canada.

Ucore is advancing its rare earth processing platform in North America, including the development of its planned SMC in Louisiana and continued commercial demonstration with the Government of Canada. SCOA has longstanding experience in the global rare earth industry, including sourcing, trading, and supply chain development.

As part of the framework, SCOA will serve as Ucore’s distribution partner for designated separated rare earth products sold to selected customer segments in Japan and other mutually agreed industrial applications.

The companies will work together to explore opportunities for cooperation across the rare earth value chain, subject to mutually agreed commercial terms and existing business arrangements.

About Ucore Rare Metals Inc.
Ucore is focused on rare- and critical-metal resources, extraction, beneficiation, and separation technologies with the potential for production, growth, and scalability. Ucore’s vision and plan is to become a leading advanced technology company, providing best-in-class metal separation products and services to the mining and mineral extraction industry.

Through strategic partnerships, Ucore aims to support the development of a more diversified and resilient North American REE supply chain through the near-term development of a heavy and light rare-earth processing facility in the US State of Louisiana, subsequent SMCs in Canada and Alaska and the longer-term development of Ucore’s 100% controlled Bokan-Dotson Ridge Rare Heavy REE Project on Prince of Wales Island in Southeast Alaska, USA (“Bokan“).

Ucore is listed on the TSXV under the trading symbol “UCU” and in the United States on the OTC Markets’ OTCQX® Best Market under the ticker symbol “UURAF.”

For further information, please visit www.ucore.com.

Forward-Looking Statements
This press release contains “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements” within the meaning of applicable Canadian securities laws. All statements in this release (other than statements of historical facts) that address future business development, technological development and/or acquisition activities (including any related required financings), timelines, events, or developments that the Company is pursuing are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance or results, and actual results or developments may differ materially from those in forward-looking statements.

For additional risks and uncertainties regarding the Company, its business activities, its ability to qualify for and receive any additional funding from any U.S. or Canadian government, the CDF and the aforementioned projects (generally), see the risk disclosure in the Company’s MD&A for Q1-2026 (filed on SEDAR+ on May 29, 2026) (www.sedarplus.ca) as well as the risks described below.

Regarding the disclosure above in the “About Ucore Rare Metals Inc.” section, the Company has assumed that it will be able to procure or retain additional partners and/or suppliers, in addition to Innovation Metals Corp. (“IMC“), as suppliers for Ucore’s expected future SMCs. Ucore has also assumed that sufficient external funding will be found to continue and complete the ongoing research and development work required at the CDF and also later prepare a new National Instrument 43-101 technical report that demonstrates that Bokan is feasible and economically viable for the production of both REE and co-product metals and the then prevailing market prices based upon assumed customer offtake agreements. Ucore has also assumed that sufficient external funding will be secured to continue the development of the specific engineering plans for the SMCs and their construction and eventual commissioning and operations.

Forward-looking statements are based on a number of material assumptions, including, without limitation: the successful completion and accuracy of baseline, front-end-engineering design and detailed engineering studies; the ability to complete further engineering, procurement, and construction activities as currently contemplated; the availability, cost, and timely delivery of equipment, materials, utilities, labour and construction services; the Company’s ability to secure sufficient financing on acceptable terms; the receipt and timing of all required permits and approvals; the successful scale-up and commercial deployment of RapidSX™ technology from demonstration to commercial operation; the availability of qualified feedstock from third-party suppliers; successful customer qualification and offtake discussions; continued support from governmental partners; and general economic, market, and industry conditions, including assumptions regarding rare earth oxide prices, which are subject to significant volatility.

Although the Company believes that the assumptions underlying the forward-looking information are reasonable, there can be no assurance that such assumptions will prove to be accurate or that the anticipated results, performance, or achievements will be realized. Actual results may differ materially from those expressed or implied by the forward-looking information.

Factors that could cause actual results to differ materially include, without limitation: risks associated with the development, scale-up, and commercialization of new or unproven technologies; the risk that RapidSX™ may not perform at commercial scale as expected; engineering design changes; inaccuracies in capital or operating cost estimates; cost escalation due to inflation, supply chain disruption, or market conditions; delays or failures in procurement, construction, or commissioning; the inability to obtain or maintain required permits, approvals, or regulatory authorizations; challenges in securing adequate financing; adverse capital market conditions; variability in feedstock supply, quality, or pricing; failure to secure or maintain commercial relationships, customer qualification, or offtake arrangements; fluctuations and uncertainty in rare earth oxide prices and demand; the risk that indicative or quoted market prices, including for ex-China markets, may not be realized; operational risks once in production, including equipment failures or lower-than-expected recoveries; geopolitical risk; changes in applicable laws or regulations; environmental or permitting challenges; loss of key personnel; and general economic, business, or competitive conditions.

Neither the TSXV nor its Regulation Services Provider (as that term is defined by the TSXV) accept responsibility for the adequacy or accuracy of this release.

CONTACTS
Mr. Peter Manuel, Ucore Vice President and Chief Financial Officer, is responsible for the content of this news release and may be contacted at 1.902.482.5214.

For additional information, please contact:
Mark MacDonald
Vice President, Investor Relations
Ucore Rare Metals Inc.
1.902.482.5214
mark@ucore.com

The issuer is solely responsible for the content of this announcement.

Frost & Sullivan White Paper Names Phancy Rise vGPU a Tier 1 Leading Platform

By
Advertorial Desk
-

Rise vGPU + ModelHub Power China’s AI into the Heterogeneous Orchestration Era


HONG KONG SAR – Media OutReach Newswire – 15 June 2026 – Frost & Sullivan, a globally renowned growth consulting firm, has released its “2026 AI Infrastructure Orchestration Platform White Paper”. The report recognizes Phancy Group’s Rise vGPU as a Tier 1 Leading Platform, the highest maturity tier in heterogeneous GPU orchestration. Phancy’s ModelHub also achieved the highest Overall Score in the enterprise-grade model management platform evaluation. This marks a significant endorsement of Phancy’s technological capability in heterogeneous AI infrastructure.

According to the white paper, as large model applications scale rapidly, China’s AI industry is facing structural challenges stemming from multi-chip coexistence. These include hardware heterogeneity, fragmented software stacks, persistently low GPU utilization (generally below 30%), and rising model adaptation complexity — all of which have become major bottlenecks for enterprise-scale AI deployment.

The report highlights a fundamental shift in AI infrastructure competitiveness – moving away from “single-chip performance” toward “cluster-scale system coordination.” At this critical juncture, Phancy has positioned itself as a leader in advanced orchestration through its full-stack AI infrastructure platform, offering a proven solution to heterogeneous compute challenges and helping drive China’s AI industry from “compute accumulation” into a new era of “compute orchestration.”

Phancy Rise vGPU: Tier 1 Leading Platform

In its assessment of mainstream AI infrastructure platforms, Frost & Sullivan defined Tier 1 criteria across three core dimensions: heterogeneous support, fine-grained control, and production-grade execution. Phancy Rise vGPU meets all three standards and has been recognized as a Tier 1 Leading Platform.

Rise vGPU transforms AI infrastructure from fragmented, low-efficiency device-level management to a unified software-defined control plane. Its key technology breakthroughs include:

  • Comprehensive Heterogeneous Management: Unified onboarding and management across more than 10 mainstream GPU/NPU vendors, including NVIDIA, Ascend, Cambricon, Hygon, and others.
  • Ultra-Fine Resource Partitioning: Industry-leading sub-GPU level compute and MB-level memory granularity slicing.
  • Significant Utilization Improvement: Through safe oversubscription and time/space multiplexing, GPU utilization is increased from industry averages below 30% to 70%-90%.
  • Intelligent Precision Scheduling: Multi-dimensional scheduling algorithms based on priority, topology, load, and resource awareness to achieve optimal compute allocation.
  • Production-Grade SLA Assurance: The Deterministic Execution Layer delivers committed and auditable SLA guarantees for critical inference workloads.
  • Full Lifecycle Operability: Comprehensive monitoring, metering, and cost allocation capabilities that turn GPU resources into truly operable digital assets.

Model Hub: Highest Overall Score in Model Management Platform Evaluation

Beyond compute orchestration, the report underscores the strategic importance of enterprise-grade model management platforms. As a powerful complement to Rise vGPU, Phancy ModelHub enables enterprises to build a complete full-stack AI infrastructure — from compute to models and from resource scheduling to business delivery.

The white paper notes that Phancy ModelHub delivers leading performance in key areas such as Model & Chip Compatibility, Execution Stability & Performance, and Model-GPU Coordination & Scheduling, achieving the highest Overall Score. Through its unified model management and execution platform, ModelHub creates a seamless closed-loop process covering model onboarding, deployment optimization, inference services, and version governance — significantly lowering the barrier to model deployment and accelerating AI innovation.

Dr. Dai Wenyuan, Founder & CEO of Phancy, said: “The Frost & Sullivan white paper accurately captures the inflection point in AI infrastructure development. The recognition of Rise vGPU as a Tier 1 Leading Platform and ModelHub’s top Overall Score provide important authoritative validation of Phancy’s technology strategy and product strength. As a full-stack AI cloud service platform, Phancy believes the next wave of competitiveness in the AI industry will come from systematic improvements in compute orchestration efficiency. We will continue to focus on heterogeneous compute unified scheduling and model ecosystem operations, working closely with customers and industry partners to advance China’s AI industry from ‘compute accumulation’ to a true ‘compute orchestration’ era.”

Hashtag: #PhancyGroup

The issuer is solely responsible for the content of this announcement.

About Phancy Group

Phancy Group (6682.HK) is a leading full-stack AI cloud services platform, providing comprehensive solutions for the AI 2.0 era. Our offerings include Rise vGPU, ModelHub and SageAIOS, delivering efficient and scalable AI infrastructure with end-to-end capabilities. We provide a complete solution from heterogeneous compute resource management and optimization to the deployment of intelligent agent models. These solutions empower digital transformation across a wide range of industries, supporting our vision of building a large-scale and efficient “Token Factory.”

Guided by the mission of “AI for Everyone” and positioned as the “Navigator of AI,” Phancy Group is committed to becoming a global leader in Artificial General Intelligence.

First Phosphate Closes Oversubscribed Private Placement to Existing and Follow-on Investors

By
Advertorial Desk
-
Saguenay-Lac-Saint-Jean, Québec – (Newsfile Corp. – June 15, 2026) – First Phosphate Corp. (CSE: PHOS) (OTCQX: FRSPF) (OTCQX ADR: FPHOY) (FSE: KD0) (“First Phosphate” or the “Company“) is pleased to announce that, on June 12, 2026, it closed its financing (the “Offering”) to existing, and other follow-on, investors on terms as described in the Company news release dated May 28, 2026.

The Company raised a total of $15,420,640 through the issuance of 1,432,750 Hard Dollar Units at a price of $2.00 per Hard Dollar Unit for gross proceeds of $2,865,500 and 6,277,570 Flow-Through Shares at a price of $2.00 per Flow-Through Share for gross proceeds of $12,555,140.

Together with this Offering, and since June 2022, the Company has raised approximately $78 million in 11 management-led non-brokered private-placement financings and from funds received from option and warrant exercise.

“With the recent entry of one of the major global mining explorers and developers into the igneous phosphate space and with the rapid onshoring of the lithium iron phosphate (“LFP”) battery industry into North America by major global cell manufacturers and LFP end-product producers to support the growing energy storage, AI data center, factory automation and national security sectors, it is crucial that First Phosphate advance strongly its exploration, development and downstream mine-to-market leadership in the igneous phosphate sector,” says First Phosphate CEO John Passalacqua. “The Company continues to view igneous phosphate in multi-generational timelines and as the new gold of the energy transition. We thank our existing and new shareholders for having supported us in this vision and having moved to position the Company to an even stronger financial position to continue with these mission critical objectives.”

In connection with the Offering, the Company paid $156,880 in cash finder’s fee, issued 322,920 compensation Common Shares at a deemed price of $2.00 per common share, and issued 401,360 Compensation Warrants, exercisable at a price of $2.50 per common share of the Company, until December 31, 2026, subject to the Accelerated Expiry Date. All securities issued under the Offering are subject to a four-month and one day statutory hold period in accordance with applicable securities laws. The Company intends to use the proceeds from the Offering as disclosed in the Company’s press release dated May 28, 2026. Capitalized terms used in this news release and not defined herein have the meanings given to them in the Company’s news release dated May 28, 2026. The Company may close another tranche of the Offering at its discretion subject to the Policies of the Canadian Securities Exchange.

Insider Participation

In connection with the Offering, Laurence W. Zeifman, Chairman of the Board of the Company, purchased 50,000 Flow-Through Shares.

About First Phosphate Corp.
First Phosphate (CSE: PHOS) (OTCQX: FRSPF) (OTCQX ADR: FPHOY) (FSE: KD0) is a mineral exploration and development and clean technology company dedicated to building and reshoring a vertically integrated mine-to-market supply chain for the production of LFP batteries in North America. Target markets include energy storage, data centers, robotics, mobility, and national security.

First Phosphate’s flagship Bégin-Lamarche property, located in Saguenay-Lac-Saint-Jean, Québec, Canada, represents a rare North American igneous phosphate resource producing high-purity phosphate characterized by very low levels of impurities.

For additional information
Bennett Kurtz
CFO, CAO
Tel : +1 (416) 200-0657

Investor Relations: https://firstphosphate.com/investors
General Inquiries: https://firstphosphate.com/contact
Website: www.FirstPhosphate.com
X : https://x.com/FirstPhosphate
LinkedIn : https://www.linkedin.com/company/first-phosphate

Forward-Looking Information and Cautionary Statement
This release includes certain statements that may be deemed “forward-looking information”. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. In particular, this press release contains forward-looking information relating to, among other things, the continued onshoring of the LFP battery industry into North America, the advancement of its exploration, development and downstream mine-to-market operations, the completion of further tranches of the Offering, the intended use of proceeds of the Offering, the availability of tax credits, and regulatory approval including the approval of the Canadian Securities Exchange (the “CSE”). Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, development and exploration successes, and continued availability of capital and financing and general economic, market or business conditions. These statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions; that the Company and other parties will be able to satisfy stock exchange and other regulatory requirements in a timely manner; that CSE approval will be granted in a timely manner subject only to standard conditions and that all conditions precedent to the completion of the Offering will be satisfied in a timely manner. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. The Company does not assume any obligation to update or revise its forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law. All forward-looking information contained in this release is qualified by these cautionary statements.

The issuer is solely responsible for the content of this announcement.

Six Regional Organisations Sign MoU to Strengthen Asia’s Dengue Response as Cases Rise

By
Advertorial Desk
-

Announced at the 9th Asia Dengue Summit in conjunction with ASEAN Dengue Day and the first WHO-recognised World Dengue Day, the MoU establishes a regional framework for knowledge-sharing, advocacy and coordinated dengue action.

SINGAPORE, June 15, 2026 /PRNewswire/ — The Asia Dengue Voice and Action Group (ADVA) and partner organisations from across Asia have signed a new regional Memorandum of Understanding (MoU) to strengthen regional cooperation on dengue prevention and control. The partnership comes at a critical time as countries face growing mosquito populations, rising dengue risks and increasing case numbers, driven in part by climate change and urbanisation in the region. 

The MoU establishes a regional framework for ongoing knowledge exchange, coordination and collaboration among advocacy groups, community organisations and public health stakeholders working to address dengue across Asia. Participating organisations will collaborate on public education, regional advocacy and the exchange of outbreak insights and community-based approaches, while exploring joint publications, policy recommendations, regional awareness campaigns, educational resources and digital knowledge-sharing platforms to support more coordinated dengue action across the region.

Signatories to the MoU include ADVA, the Philippines Empowering Networks to Defeat Dengue Coalition (END Dengue), Dengue Prevention Advocacy Malaysia (DPAM), Indonesia’s Kobar Lawan Dengue, the Singapore Dengue Alliance, and the International Society for Neglected Tropical Diseases (ISNTD). As the convening organisation, ADVA will facilitate engagement on emerging insights, common challenges and explore opportunities for collective action.

Professor Tikki Pangestu, Advisor, ADVA and Visiting Professor, Yong Loo Lin School of Medicine, National University of Singapore, said, “There is no single solution to dengue. Sustainable progress requires a holistic approach that brings together effective surveillance, vector control, clinical management, community education and vaccination. As countries across Asia continue to face a growing dengue burden, it is essential that we learn from one another’s experiences and work together to accelerate the adoption of evidence-based strategies. This partnership reflects a shared commitment to strengthening regional collaboration and advancing practical solutions that can help move us closer to the goal of zero dengue deaths.”

The MoU was signed on ASEAN Dengue Day and the first World Health Organisation (WHO)-recognised World Dengue Day in the presence of Guest of Honour Dr Janil Puthucheary, Senior Minister of State, Ministry of Sustainability and the Environment and Ministry of Education, Singapore, as well as ambassadors and diplomatic representatives representing countries across Asia, Europe, Latin America, Africa and the Middle East. The ceremony was part of the 9th Asia Dengue Summit – a regional platform that brings together policymakers, scientists, clinicians, public health experts and advocacy groups to advance dengue prevention and response across Asia.

Professor Ooi Eng Eong, from the Emerging Infectious Diseases Signature Research Programme at Duke-NUS Medical School, said, “We are at a very different point in the dengue response today compared with a decade ago. Advances in surveillance, vector control and vaccination have expanded what countries can do, but progress remains uneven. The next challenge is implementation: ensuring that these advances are used consistently, sustained beyond outbreak periods and translated into measurable public health impact. That will be critical if the region is to move closer to Zero Dengue Deaths by 2030.”

Associate Professor Ng Lee Ching, Group Director of Environmental Health Institute (EHI), National Environment Agency (NEA) Singapore, said, “Dengue control cannot rely on a single intervention or a single agency alone. Singapore’s experience has shown that sustained surveillance, clinical management, vector control, public awareness and community participation all play an important role in managing dengue risks. Maintaining a multi-sectoral effort consistently over time remains critical, even outside major outbreak periods.”

Running from 15–17 June, the Summit brings together stakeholders from across the dengue control ecosystem to bridge the gap between scientific progress and real-world impact. Through discussions on dengue policy, scientific innovation, vector control, vaccine implementation and youth engagement initiatives such as the Dengue Slayers Challenge, participants will explore how progress in dengue prevention and control can be translated into greater public health impact across the region.

For more information about the 9th Asia Dengue Summit or to access resources on dengue prevention and advocacy, visit https://www.asiadenguesummit.org/ or https://www.adva.asia/. 

About ADVA
Asia Dengue Voice and Action (ADVA) is a scientific working group dedicated to dengue vaccine advocacy in Asia, with the aim of disseminating information and making recommendations on dengue vaccine introduction strategies in Asia. The group has formulated recommendations with an ultimate aim of translating the science of dengue vaccination into messages for policy makers, general public and health care workers. For more information, visit https://www.adva.asia/ 

APP Group Highlights the Role of Sustainable Products for Hospitality and F&B Ahead of World Cup 2026

By
Advertorial Desk
-

ORANGE, Calif., June 15, 2026 /PRNewswire/ — APP Group highlights the growing role of sustainable paper-based products for hospitality and food and beverage businesses as they prepare for World Cup 2026. With 48 teams and 104 matches across Canada, Mexico, and the United States, the tournament is expected to bring a sharp rise in visitors, meals served, and on-the-go consumption across host cities.

The waste challenge is already visible from past tournaments. During the previous World Cup, more than 2,100 tonnes of stadium waste were collected, including 202 tonnes of plastic materials, 65 tonnes of paper and cardboard, 60 tonnes of metals, and 4 tonnes of glass. For hotels, restaurants, cafés, caterers, and event venues, sustainability will increasingly be shaped by practical everyday choices: how food is presented, how takeaway orders are packed, and what materials are used in high-volume service.

“Sustainability in hospitality is often shaped by the small details guests interact with every day, from packaging to tissue products,” said Ian Lifshitz, Head of Sustainability & Public Affairs for the Americas at APP Group. “Through Foopak and our broader sustainability commitments, we aim to support businesses in making choices that are practical, responsible, and ready for high-volume service environments.”

Foopak, APP Group’s paperboard brand, provides certified, eco-friendly packaging for F&B businesses. Foopak Bio Natura is a plastic-free, PFAS-free, and compostable solution safe for direct food contact. Designed for high-volume applications like cups and trays, it helps brands reduce environmental impact while maintaining high performance and quality.

For APP Group, Foopak is part of a broader sustainability journey. Through Regenesis, the company brings together commitments on forest conservation and restoration, carbon management, production innovation, community empowerment, and long-term partnerships. World Cup 2026 offers the hospitality and F&B sectors a chance to prioritize sustainable guest experiences. Through Foopak and Regenesis, APP Group provides functional, scalable solutions to help the industry transition toward environmentally thoughtful service.

About APP Group
APP Group is a leading Indonesia-based pulp, paper, and forestry company supplying tissue, packaging, and paper products to more than 150 countries. Operating in Indonesia and China, APP integrates responsible sourcing and sustainability into its business strategy through its Sustainability Roadmap Vision 2030. The company also introduced Regenesis, its platform to advance long-term environmental and social commitments.

Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026

By
Advertorial Desk
-

– BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 –

– BBT002 demonstrated rapid, deep, and sustained biomarker effects through at least 8 weeks following multiple doses, consistent with the SAD data, with a ~29.4-day half-life supporting extended dosing intervals –

– Topline data from ongoing proof-of-concept trials evaluating BBT002 in patients with COPD and CRSwNP anticipated by year-end 2026 and first half of 2027, respectively –

BOSTON, June 15, 2026 /PRNewswire/ — Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation, long-acting bispecific antibodies for immunology and inflammation, today announced positive preliminary data from the multiple ascending dose (MAD) cohorts of its Phase 1 trial evaluating BBT002 in healthy volunteers. The results were reviewed in an oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place from June 12-15, 2026 in Istanbul, Turkey.

“We are highly encouraged by the preliminary Phase 1 multiple ascending dose data of BBT002 and were pleased to present these results at the EAACI Annual Congress—one of the leading global gatherings of allergy and immunology professionals,” said Thang Ho, Ph.D., Chief Development Officer at Bambusa Therapeutics. “Building on the SAD data we recently shared, the Phase 1 MAD data further support BBT002 as a potentially differentiated, long-acting bispecific antibody targeting IL-4Rα and IL-5 to address multiple complementary drivers of Type 2 inflammation. BBT002 continues to demonstrate rapid, deep, and sustained biologic activity across multiple clinically relevant biomarkers, including eosinophils, TARC, and pSTAT6, while also supporting the potential for extended dosing intervals through prolonged half-life. We believe these findings reinforce the opportunity for BBT002 to deliver more comprehensive disease control and enhanced dosing convenience for patients with respiratory and other eosinophil-driven inflammatory diseases.”

The presentation titled “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT002, a Novel Bispecific IL-4Rα/IL-5 Antibody: Results from the Single- and Multiple-Ascending Dose Portions of a Phase 1 Study of Healthy Volunteers” highlighted the following data:

Percent Change in Eosinophil (EOS) Levels: EOS is a clinically established biomarker of Type 2 airway inflammation and IL-5 pathway activity, with elevated levels associated with disease severity and exacerbation risk across multiple respiratory diseases.

  • BBT002 demonstrated rapid, robust, and sustained depletion of EOS for more than 8 weeks following multiple doses compared to baseline.

Percent Change in Thymus and Activation-Regulated Chemokine (TARC): TARC is a key Type 2 inflammatory chemokine that is associated with Th2-driven immune responses and is strongly correlated with disease activity across multiple respiratory inflammatory diseases.

  • BBT002 demonstrated dose-dependent, rapid, deep, and sustained reduction in TARC levels following multiple doses compared to baseline.

Percent Change in Phosphorylated STAT6 (pSTAT6): pSTAT6 is a key downstream mediator of Type 2 inflammation in respiratory inflammatory disease when assessing IL-4Rα pathway activity.

  • BBT002 achieved rapid, complete, and sustained inhibition of pSTAT6 for more than 8 weeks following multiple doses compared to baseline.

Pharmacokinetics (PK): BBT002 exhibited prolonged PK with a half-life of approximately 29.4 days at or above target exposure, consistent with the PK profile observed in the single ascending dose (SAD) cohorts, supporting the potential for extended dosing intervals.

Safety and Tolerability: BBT002 was observed to be well-tolerated across all doses evaluated in the SAD (previously presented at ATS 2026) and MAD cohorts throughout the trial.

Immunogenicity: The incidence and titer of anti-drug antibodies (ADA) was low, with no apparent impact on safety or PK.

“The growing body of clinical data emerging across our pipeline continues to support Bambusa’s strategy of developing next-generation bispecific antibodies designed to address multiple drivers of inflammation within a single molecule,” said Shanshan Xu, M.D., Ph.D., Founder & Chief Executive Officer of Bambusa Therapeutics. “As we advance BBT002 in ongoing clinical studies in patients with COPD and CRSwNP, we remain focused on evaluating its potential to deliver differentiated clinical benefit across Type 2 inflammatory diseases. In parallel, we look forward to reporting topline data this summer from our ongoing BBT001 study in atopic dermatitis. We believe these data have the potential to establish proof-of-concept for BBT001 and further inform the clinical potential of dual IL-4Rα and IL-31 inhibition in patients with atopic dermatitis.”

In parallel to the Phase 1 SAD and MAD cohorts in healthy volunteers, BBT002 is being evaluated in ongoing proof-of-concept trials in patients with chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP), with topline results anticipated by year-end 2026 and the first half of 2027, respectively.

The BBT002 Phase 1 healthy volunteer data presentation from EAACI 2026 is available in the “Publications” section on Bambusa’s website, www.bambusatx.com.

About the BBT002 Phase 1 SAD/MAD Healthy Volunteer Study Cohorts

Bambusa Therapeutics’ single- and multiple-ascending-dose Phase 1 clinical trial in healthy volunteers is a randomized, blinded, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamic profile of BBT002.

About BBT002

Bambusa Therapeutics’ second clinical program, BBT002, is a first-in-class, multi-targeting, half-life extended bispecific antibody engineered to inhibit both IL-4Rα and IL-5 signaling. Designed as a platform-in-a-molecule, BBT002 simultaneously targets the IL-4/IL-13 pathway through IL-4Rα and the IL-5/eosinophil axis within a single therapy. We believe this differentiated approach has the potential to address multiple respiratory and other Type 2 inflammatory diseases, improve clinical outcomes, and provide greater dosing convenience through extended maintenance dosing intervals.

About Bambusa Therapeutics

Bambusa Therapeutics is a clinical-stage biotechnology company developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation (I&I) diseases. The Company’s bispecific antibody platform combines advanced protein engineering with half-life extension technology and high-concentration subcutaneous delivery to improve durability, convenience, and clinical differentiation. Bambusa’s vision is to deliver transformative medicines for patients across every stage of life and help define the next era of I&I therapies.

  • BBT001 is a first-in-class, half-life-extended bispecific antibody targeting IL-4Rα and IL-31 with best-in-disease potential. It is currently in Phase 1 proof-of-concept development for atopic dermatitis (AD) and chronic spontaneous urticaria (CSU).
  • BBT002 is a first-in-class, half-life-extended bispecific antibody targeting IL-4Rα and IL-5 with platform-in-a-molecule potential. It is currently in proof-of-concept development for Type 2 inflammatory disorders including COPD and CRSwNP.
  • BBT003 and BBT004 are preclinical programs focused on gastroenterology and autoimmune diseases, respectively.

For more information, please visit www.bambusatx.com. Follow Bambusa on LinkedIn.

ONLYOFFICE DocSpace 3.7 released: AI file generation, smarter forms, and updated editors

By
Advertorial Desk
-

SINGAPORE, June 15, 2026 /PRNewswire/ — ONLYOFFICE releases DocSpace 3.7, the newest version of its room-based collaboration platform. A major update adds new AI capabilities, a redesigned form filling experience, updated editors, and stronger security controls. The release touches nearly every part of the platform and is already available for users.

ONLYOFFICE DocSpace 3.7 released.
ONLYOFFICE DocSpace 3.7 released.

The update expands how AI agents work inside DocSpace. Users can now generate DOCX files, PDF forms, and PPTX presentations directly from the AI chat and open them right away for editing. The release also adds support for new providers, including DeepSeek, Google AI, and xAI, alongside existing options such as Anthropic, OpenAI, and OpenRouter.

AI setup gets more flexible. A default provider and model selected in DocSpace can sync automatically to the editors, removing the need for separate configuration. Users can upload images into the AI chat to give agents visual context, while an optional extended thinking section appears for more complex requests. Moreover, administrators can turn AI features on or off across DocSpace and the editors, with chat history preserved when disabled.

Form Filling rooms received one of the largest updates in this release. Beyond collecting responses in a spreadsheet, teams can export results to an external database. Users can create and edit PDF forms directly in the room, switch forms into a dedicated filling mode, and refresh collected data.

DocSpace 3.7 also includes editors powered by ONLYOFFICE Docs 9.4. Enhancements comprise horizontal lines for clearer document structure, Dark Document mode in spreadsheets, 25 new slide themes, 20 new transitions, a dedicated Chart Design tab, and Croatian interface support.

File and room management improvements give users more control over their space. Teams can replace default document templates, combine rooms into groups, delete multiple rooms at once, and manage room tags more quickly.

On the security side, administrators are able to prohibit the creation of external links to protect sensitive content. Invite links can now be limited by the number of users who join and by how long the link stays valid. A new Billing section unifies tariff plans, the Wallet, payment methods, and additional services such as extra storage and backup.

This release updates ONLYOFFICE licensing terms for added clarity and compliance. The software code is licensed under the GNU Affero General Public License v3.0 (AGPLv3), with additional terms covering attribution and modified versions. The license does not grant rights to ONLYOFFICE trademarks, which remain governed by a separate Trademark Policy.

About ONLYOFFICE

ONLYOFFICE is a provider of secure online office and collaboration tools, including document editors, the DocSpace collaboration platform, and a range of integrations. Trusted by organizations and individuals worldwide, ONLYOFFICE focuses on data privacy, format compatibility, and flexible deployment across cloud and on-premises environments.

Media contact: marketing@onlyoffice.com +37163399867

Official website: www.onlyoffice.com 

1...301302303...6,528Page 302 of 6,528